ProKidney (PROK) Stock Price, News & Analysis

Company Overview

ProKidney Corporation is a biotechnology company focused on developing cell-based therapies for chronic kidney disease (CKD). The company’s lead investigational product is rilparencel, formerly known as REACT, an autologous cell therapy made from a patient’s own kidney cells.

Rilparencel is designed to be injected into the patient’s kidneys, where the cells are intended to support kidney function and potentially slow the progression of CKD. ProKidney is studying the therapy primarily in patients with diabetic kidney disease and advanced CKD, with the goal of delaying or reducing the need for dialysis or kidney transplantation.

ProKidney’s operations are centered on the development and clinical testing of rilparencel, and the company does not currently have an approved commercial product. Its programs have included clinical studies in the United States and other regions as it evaluates the safety and efficacy of its kidney cell therapy.

The company became a publicly traded entity in 2022 through a business combination with Social Capital Suvretta Holdings Corp. III and began trading on the Nasdaq under the symbol PROK.

Key Stats

• Today's Range: $1.43 to $1.53
• 50-Day Range: $1.33 to $2.01
• 52-Week Range: $1.30 to $3.27
• Volume: 817,574 shs
• Average Volume: 1.11 million shs
• Market Capitalization: $444.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Moderate Buy

ProKidney Stock Analysis - MarketRank™

ProKidney scored higher than 41% of companies evaluated by MarketBeat, and ranked 694th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ProKidney has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

ProKidney has a consensus price target of $10.00, representing about 580.3% upside from its current price of $1.47.

Amount of Analyst Coverage

ProKidney has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for ProKidney are expected to decrease in the coming year, from ($0.51) to ($0.75) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ProKidney is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ProKidney is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.50% of the float of ProKidney has been sold short.

Short Interest Ratio / Days to Cover

ProKidney has a short interest ratio ("days to cover") of 20.77, which indicates bearish sentiment.

Change versus previous month

Short interest in ProKidney has recently increased by 3.28%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ProKidney does not currently pay a dividend.

Dividend Growth

ProKidney does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.32

News Sentiment

ProKidney has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for ProKidney this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added ProKidney to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ProKidney insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,067,315.00 in company stock.

Percentage Held by Insiders

39.83% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

51.59% of the stock of ProKidney is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/29/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PROK
• CIK: 1850270
• Web: www.prokidney.com
• Phone: 336-999-7028
• Fax: N/A
• Employees: 231
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ProKidney: $10.00
• High Price Target: $12.00
• Low Price Target: $8.00
• Potential Upside/Downside: +580.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68.99 million
• Net Margins: -10,288.39%
• Pretax Margin: -20,388.38%
• Return on Equity: N/A
• Return on Assets: -27.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.36
• Quick Ratio: 8.36

Sales & Book Value

• Annual Sales: $818 thousand
• Price / Sales: 543.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.36) per share
• Price / Book: -0.44

Miscellaneous

• Outstanding Shares: 302,323,000
• Free Float: 181,908,000
• Market Cap: $444.41 million
• Optionable: Optionable
• Beta: 1.77